# UNITED STATES
# SECURITIES AND EXCHANGE COMMISSION
**WASHINGTON, DC 20549**

# FORM 8-K

**CURRENT REPORT**
**Pursuant to Section 13 or 15(d) of the**
**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): January 10, 2022**

# EyePoint Pharmaceuticals, Inc.
**(Exact Name of Registrant as Specified in Charter)**

| **Delaware** | **000-51122** | **26-2774444** |
|---|---|---|
| **(State or Other Jurisdiction of Incorporation)** | **(Commission File Number)** | **(I.R.S. Employer Identification No.)** |

**480 Pleasant Street**
**Watertown, MA 02472**
**(Address of Principal Executive Offices, and Zip Code)**

**(617) 926-5000**
**Registrant's Telephone Number, Including Area Code**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
|---|---|---|
| **Common Stock, par value $0.001** | **EYPT** | **The Nasdaq Stock Market LLC** |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01. Other Events.**

On January 10, 2022, EyePoint Pharmaceuticals, Inc. (the "Company") issued a press release summarizing its 2022 clinical plans and highlighting recent corporate and clinical achievements. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

On the same date, the Company posted an updated corporate presentation on its website at www.eyepointpharma.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release of EyePoint Pharmaceuticals, Inc., dated January 10, 2022 |
| 99.2 | Corporate Presentation, dated January 10, 2022 |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**EYEPOINT PHARMACEUTICALS, INC.**

Date: January 10, 2022

By: /s/ George O. Elston
Name: George O. Elston
Title Chief Financial Officer

**Exhibit 99.1**

**EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements**

– Updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD continue to show positive safety and efficacy results out to eight months. Further results to be presented at the February Angiogenesis 2022 virtual meeting –

– Phase 2 study for EYP-1901 in wet AMD expected to initiate in Q3 2022 guided by positive Type C meeting with FDA –

– Announces appointment of Michael C. Pine as Chief Corporate Development and Strategy Officer –

– Record customer demand in Q4 2021 for YUTIQ® and DEXYCU® of approximately 650 and 13,800, units and increases of 16% and 5%, respectively from Q3 2021 –

– DEXYCU alliance with Harrow Health continues EyePoint's pivot to being a retina-focused company –

– Cash and investments of approximately $210M at December 31, 2021 –

WATERTOWN, Mass, January 10, 2022 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced its 2022 clinical pipeline plans and highlighted recent corporate achievements driven by its lead pipeline candidate, EYP-1901, a potential six-month intravitreal treatment targeting wet age-related macular degeneration (wet AMD).

"We are extremely proud of our significant progress and growth in 2021, as we successfully initiated, enrolled and reported positive data for our Phase 1 study of EYP-1901 for wet AMD, positioning the program for multiple Phase 2 trials in 2022 after a positive Type C meeting with the FDA in December and bringing us closer to potentially changing the standard of care for patients," said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals. "We also significantly improved our balance sheet and ended 2021 with approximately $210 million in cash and investments, providing us with a strong foundation as we work to expand our pipeline with additional programs."

Ms. Lurker continued, "As we look ahead to 2022, EyePoint is focused on pipeline growth and expansion, with the ultimate goal of improving the lives of patients with serious eye disorders and bringing innovative products to patients in the United States and around the world. We look forward to continued advancement of our programs through clinical development, while also positioning our commercial franchises, DEXYCU® and YUTIQ®, to breakeven in 2022."

**2022 Clinical Plans**

- Updated eight-month data from the Phase 1 DAVIO study of EYP-1901 for wet AMD has 7 of 17 patients (41%) out to eight months rescue free and continued positive safety profile. Detailed data will be presented on February 12, 2022 at the Angiogenesis 2022 virtual meeting.
- Initiate a randomized, controlled Phase 2 study of EYP-1901 for wet AMD in Q3 2022. The twelve-month wet AMD Phase 2 trial is expected to enroll 144 patients, randomly assigned to one of two doses of EYP-1901(approximately 2mg or 3mg) or aflibercept control with efficacy endpoints of

change in BCVA (best corrected visual acuity), change in CST (central subfield thickness as measured by OCT), time to rescue and safety.
- Initiate a randomized, controlled Phase 2 study of EYP-1901 in diabetic retinopathy (DR) in 2H 2022.
- Continue investment in clinical and R&D organization to support pipeline expansion and growth.

**Recent Company Highlights**

Research and Development

- Completed a collaborative and positive Type C meeting with the FDA on December 1, 2021, obtaining specific guidance on both Phase 2 and future pivotal studies for EYP-1901.
- Reported positive interim six-month safety and efficacy data from Phase 1 DAVIO study of EYP-1901 for the potential treatment of wet AMD at the American Academy of Ophthalmology annual meeting in November 2021.

Corporate

- Q4 2021 customer demand of approximately 650 units of YUTIQ and 13,800 units for DEXYCU, compared to approximately 560 units and 13,100 units, respectively for Q3 2021.
- Approximately $210M in cash and investments at December 31, 2021 including over $230 million in proceeds from two successful follow-on offerings during the year.
- Expanded U.S. commercial alliance with Harrow Health's division ImprimisRx, whereby ImprimisRx will assume full responsibility for U.S. sales and marketing activities of DEXYCU and absorb the majority of EyePoint's DEXYCU commercial organization. EyePoint has retained DEXYCU's NDA, revenue recognition, manufacturing and distribution responsibilities for all markets. This transaction continues EyePoint's pivot to being a retina-focused ophthalmology company.
- Strengthened leadership team with the appointment of Dr. Jay Duker, MD, to Chief Operating Officer in November 2021 and Michael C. Pine as Chief Corporate Development and Strategy Officer in January 2022.

**About EyePoint Pharmaceuticals**

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following ocular surgery. DEXYCU is now sold in the U.S. by ImprimisRx, a division of Harrow Health. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates,"

“estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes uncertainties regarding the timing and clinical development of our product candidates, including EYP-1901; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the continued impact of the COVID-19 pandemic on EyePoint's business, the medical community and the global economy and the impact of general business and economic conditions; the success of current and future license agreements; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; manufacturing risks; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

**For EyePoint Pharmaceuticals:**
**Investors:**
Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

**Media Contact:**
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

Exhibit 99.2

# Delivering Innovation to the Eye

## Investor Presentation
## January 2022

EYEPOINT PHARMACEUTICALS

# Forward looking statements

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the potential benefits of our partnerships and strategic alliances with other companies, as well as the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a vital, novel twice-yearly treatment for wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the extent to which COVID-19 impacts our business; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ® and DEXYCU® and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; the success of current and future license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; termination or breach of current license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

COMPANY OVERVIEW

# Pipeline leveraging proven Durasert® technology *

## Compelling pipeline focused on retinal disease

- EYP-1901 - advancing into phase 2 trials for wet AMD, diabetic retinopathy (DR), and retinal vein occlusion (RVO) after positive phase 1 interim results and positive Type C FDA meeting guidance
- Additional molecules and MOAs under evaluation

## Durasert® - proven intravitreal (IVT) drug delivery platform

- Sustained local drug delivery
- Constant (zero-order kinetics), stable release of drug in the eye over weeks, months or years
- Safely administered to thousands of patients' eyes across four FDA approved products

## Commercial franchises - YUTIQ® and DEXYCU®

- Positioned to break-even in 2022 as stand-alone franchise
- YUTIQ 50 in Phase 3 study supporting an sNDA filing
- DEXYCU sales and marketing now managed by commercial partner ImpriminsRx as we focus on retina



*non-erodible

PLATFORM TECHNOLOGY

# DURASERT®

## Proven sustained release intravitreal drug delivery



TECHNOLOGY

# DURASERT®

## Proven safe, sustained intravitreal delivery

- Delivered by a simple, single in-office intravitreal injection
- Continuous, stable release provides consistent and reliable drug delivery over weeks, months, or years

### Approved Products

- YUTIQ® (2018, EyePoint) Posterior Segment Uveitis
- ILUVIEN® (2014, Alimera) - DME
- RETISERT® (2005, B&L) - Uveitis
- VITRASERT® (1996, B&L) - CMV retinitis

### Development Candidates

- EYP-1901
  - Wet AMD
  - Diabetic Retinopathy (DR)
  - Retinal Vein Occlusion (RVO)
- YUTIQ® 50
  - Posterior Segment Uveitis

# Retinal disease focused pipeline

| DURASERT PROGRAM | PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| **EYP-1901- VOROLANIB (TKI)**<br>• Wet AMD<br>• Diabetic retinopathy<br>• Retinal vein occlusion | | | | |
| **YUTIQ® 50 - (FA)**<br>• Posterior segment uveitis under sNDA plan | | | | |
| **Evaluating Pre-Clinical Programs** | | | | |



PIPELINE

# EYP-1901 – IVT delivery of vorolanib using bioerodible Durasert® as a potential six-month treatment

## Our goal is nothing short of transforming the treatment of wet AMD, diabetic retinopathy, and retinal vein occlusion

PIPELINE

**EYP-1901**



VOROLANIB | DURASERT

# Real World Reality – Even One Missed Injection Can Mean Loss of Vision

AMERICAN ACADEMY OF OPHTHALMOLOGY®

## The Effect of Delay in Care among Patients Requiring Intravitreal Injections

*Weilin Song, BS,[1] Rishi P. Singh, MD,[2] Aleksandra V. Rachitskaya, MD[3]*

- Study evaluated 1,041 pts getting intravitreal anti-VEGF therapies
- 60% went to scheduled follow up - 40% did not
- Conclusion: With frequent injections required for current standard of care, a delay in care of only 5.34 weeks resulted in visual loss
- Sustained release options may give practitioners and patients improved outcomes

# EYP-1901 – A Novel Approach to Wet AMD Therapy
# Vorolanib in Bioerodible Durasert®



*EYP-1901 insert at month 5 post-injection*

## Bioerodible Durasert® :

Similar technology used in YUTIQ®, Retisert®, and Vitrasert®

- Polyimide shell removed (used for 3-year duration)
- Bioerodible core matrix remains
- Initial burst from the surface of implant
- Constant, zero-order kinetic release rate for months

## vorolanib

- Receptor-binding, small molecule tyrosine kinase inhibitor (TKI)
- Activity against all isoforms of VEGF and PDGF
- Oral vorolanib previously studied in a wet AMD ph1 and ph2 programs[1,2]



1. Jackson et al. JAMA Ophthalmol 2017
2. Cohen MN et al. Br J Ophthalmol. 2021

PIPELINE

# EYP-1901



VOROLANIB | DURASERT

## Effective blocking of VEGFR Prevents Exudation and Loss of Vision

### VEGF SIGNALING PATHWAYS



# EYP-1901 – Intellectual Property Overview




- USFDA Exclusivity
  - Potential 5 years for new chemical entity or 3 years for new clinical investigation
- In-Licensed Patents and Applications
  - US patents expiring in 2027
  - US patent expiring in 2037, and related pending US application
  - Ex-US patents and pending patent applications
- EyePoint Patent Applications
  - International Patent Application (PCT) filed in September 2021
  - US provisional application filed in October 2021


EYP-1901 phase 1 trial
interim results

# EYP-1901 –DAVIO Phase 1 Study in Wet AMD "Durasert and Vorolanib in Ophthalmology"

## 6-month interim data summary: All study objectives successfully met

**SAFETY**

**Positive safety data:**

- No ocular Serious Adverse Events (SAEs) reported
- No drug-related systemic SAEs reported
- All ocular AEs were ≤ grade 2; the only grade 3 AE was not drug-related

**EFFICACY**

**Positive efficacy Data:**

- Stable VA and OCT
- Median time to rescue: 6 months
- Clinically significant reduction in treatment burden

# EYP-1901 - DAVIO Phase 1 Study in Wet AMD

***Open label, Dose Escalation, No Control Arm***

## Enrollment

- Previously treated wet AMD eyes only
- No exclusion for presence of fluid

## NO mandated EYP 1901 retreatments

**Criteria for rescue anti-VEGF therapy*:**

- New fluid > 75 microns (OCT) compared to Day-0
- ≧ 2 lines of BCVA secondary to wet AMD compared to Day-0
- New macular hemorrhage secondary to wet AMD

## Primary endpoint: safety

- Interim at month-6
- Full readout at month-12

**Secondary endpoints:**

- BCVA
- CST as measured by OCT

**at the discretion of the investigator*






Note: All doses delivered in a single intravitreal injection.
BCVA: best corrected visual acuity; OCT: optical coherence tomography; CST: central subfield thickness

# EYP-1901 Phase 1 DAVIO Study Participants and 6-month Follow-Up

| Screening Characteristics (N=17) and Follow Up Visits | |
|---|---|
| Mean age, range (years) | 77.4 (67–94) |
| Female (n, %) | 13/17 (76%) |
| Mean BCVA, range (ETDRS letters) | 69 letters, (38-85) |
| Mean CST, range (microns) | 299 microns, (204–441) |
| Median length of time for wet AMD diagnosis prior to enrollment | 17 months |
| Mean # of injections per year prior to enrollment | 8.76 injections/year |
| Follow Up at 6 months | 168 out of 170 (99 %) possible post treatment follow up visits performed |



BCVA: best corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; CST: central subfield thickness


EYP-1901 Phase 1 DAVIO Study
6-Month Results: Safety
EYEPOINT
PHARMACEUTICALS
16 | EYEPOINT PHARMACEUTICALS

# EYP-1901 – Phase 1 DAVIO Study
# Primary Endpoint – Safety at 6 months

**Positive overall safety data**
**No ocular serious adverse events (SAEs) reported**
**No drug-related systemic SAEs reported**

***No other reported significant adverse events such as:***

- No vitreous floaters
- No endophthalmitis
- No retinal detachment
- No implant migration in the anterior chamber
- No retinal vasculitis
- No posterior segment inflammation

***Ocular AEs:***

- One eye: mild asymptomatic anterior chamber cell/flare; *Treated with Maxitrol® eyedrops – resolved in 8 days –no sequelae or recurrence*
- One eye: asymptomatic vitreous hemorrhage from injection; *Observed*



AC, anterior chamber; AE, adverse event; BCVA, best corrected visual acuity; SAE, serious adverse event

# EYP-1901 - Phase 1 DAVIO Study
# Summary at 6 Months - Ocular Safety

**Treatment Ocular Adverse Events as Occurring by Subject**

| Event | 440 µg (n=3) | 1030 µg (n=1) | 2060 µg (n=8) | 3090 µg (n=5) | Total (N=17) |
|---|---|---|---|---|---|
| Ocular SAEs | 0 | 0 | 0 | 0 | 0 |
| Dose-limiting toxicity events | 0 | 0 | 0 | 0 | 0 |
| Vitreous floaters | 0 | 0 | 0 | 0 | 0 |
| Endophthalmitis | 0 | 0 | 0 | 0 | 0 |
| Reduction in BCVA ≥10 letters[a] | 1 | 0 | 1 | 1 | 3 |
| Retinal detachment | 0 | 0 | 0 | 0 | 0 |
| Implant migration into AC | 0 | 0 | 0 | 0 | 0 |
| Ocular inflammation | 0 | 0 | 1 | 0 | 1 |
| Elevated IOP | 1 | 0 | 0 | 0 | 1 |
| Post-treatment ocular pain/discomfort | 2 | 0 | 1 | 0 | 3 |
| Progressive disease activity | 1 | 0 | 2 | 8 | 11 |
| Subconjunctival hemorrhage | 0 | 0 | 3 | 1 | 4 |
| Vitreous haze | 0 | 0 | 0 | 0 | 0 |
| Dry eye syndrome OU | 1 | 0 | 0 | 0 | 1 |
| Worsening cataracts OU | 0 | 0 | 1 | 0 | 1 |
| Worsening meibomian gland dysfunction OU | 0 | 0 | 1 | 0 | 1 |
| Silicone oil bubble | 0 | 0 | 1 | 0 | 1 |
| Lid edema | 0 | 0 | 1 | 0 | 1 |
| Ocular discharge | 0 | 0 | 1 | 0 | 1 |
| Vitreous hemorrhage | 0 | 0 | 0 | 1 | 1 |
| Corneal epitheliopathy secondary to dry eye (OS) | 0 | 0 | 1 | 0 | 1 |
| Flame shaped hemorrhage | 1 | 0 | 0 | 0 | 1 |
| Macular hemorrhage | 1 | 0 | 0 | 0 | 1 |

AEs of particular interest



a. All mild-to-moderate in severity and determined not related to study drug
b. Grade 1/Mild

AC anterior chamber; AE, adverse event; BCVA, best corrected visual acuity; OS, left eye; OU; both eyes


EYP-1901 Phase 1 DAVIO Study
6 Month Results: visual acuity, CST, rescue free rates, and reduction in treatment burden
EYEPOINT
PHARMACEUTICALS
19 | EYEPOINT PHARMACEUTICALS

# EYP-1901 – Phase 1 DAVIO Study
## *Average Visual Acuity (VA) Stable 6 Months After Treatment*

### Average change in BCVA from screening visit




**For all 17 eyes at 6 months VA = -2.5 letters**

BCVA: best corrected visual acuity

*Interim data – monitored through 6 months*

# EYP-1901 - Phase 1 DAVIO Study

## *Central Subfield Thickness (CST) Sustainable Anatomical Control & Efficacy*

### Average change in CST from screening visit






OCT: optical coherence tomography; CST: central subfield thickness

*Interim data – monitored through 6 months*

# EYP-1901 Phase 1 DAVIO Study

## Rescue-free Rates up to Each Visit: Entire Study group






*Interim data – monitored through 6 months*

# EYP-1901 Phase 1 DAVIO Study
## Rescue-free Rates up to Each Visit






*Interim data – monitored through 6 months*

# EYP-1901 Phase 1 DAVIO Study

## Details on Patients (n=9) That Received Rescue Anti-VEGF Therapy Up to six months

| Cohort | Subject # | Rescue Visit | Reason |
|---|---|---|---|
| Low Dose | 2 | Month 1 | Rescued for CST |
| Low Dose | 3 | Month 5 | Rescued for CST |
| Mid Dose | 6 | Month 5 | Rescued for CST |
| Mid Dose | 7 | Month 5 | Rescued for VA |
| Mid Dose | 10 | Month 4 | Rescued for CST |
| Mid Dose | 12 | Month 3 | Rescued for VA |
| High Dose | 13 | Month 1 | new IRF – did not meet criteria |
| High Dose | 15 | Month 1 | Rescued for CST |
| High Dose | 17 | Month 6 | Rescued for CST |

CST: central subfield thickness; SRF: subretinal fluid; IRF: intra-retinal fluid



*CST's NOT Reading Center Confirmed - Interim data – monitored through 6 months*

# EYP-1901 Phase 1 DAVIO Study – 6 Month Results

## Clinically Significant Reduction in Treatment Burden - *79 % for the entire cohort*

### SOC Anti-VEGF Injections Before and After Treatment




Average Monthly TX Burden

| | Prior period | 6m period after | ↓% |
|---|---|---|---|
| Low dose (n=3) | 0.74 | 0.22 | -70% |
| Low-mid dose (n=1) | 0.78 | 0 | -100% |
| Mid dose (n=8) | 0.78 | 0.08 | -89% |
| High dose (n=5) | 0.59 | 0.23 | -61% |

● Anti-VEGF ○ No rescue injection given □ Missed visit

*Interim data – monitored through 4 months*

# EYP-1901 Phase 1 DAVIO Study

## Case 1: Entered Dry, Stayed Dry for 9 Months

*Low dose cohort (EYP-1901 440 µg)*

### Screening visits prior to treatment

**Initial Diagnosis:** *9 months prior to enrollment*



**Screening Visit:** *6 anti-VEGF injections prior to enrollment*



# EYP-1901 Phase 1 DAVIO Study

## Case 1: Post-Treatment (No Rescues Through Month 9)

*Low dose cohort (EYP-1901 440 µg)*



# EYP-1901 Phase 1 DAVIO Study

## Case 2: Rescued at Month 1 and failure of both SOC and EYP-1901

*Low dose cohort (EYP-1901 440 µg)*

### Prior to Treatment

Screening Visit (9 prior anti-VEGF injections)



# EYP-1901 Phase 1 DAVIO Study

## Case 2: Rescued at Month 1 and failure of both SOC and EYP-1901

***Low Dose Cohort (EYP-1901 440 µg)***



















**Despite early rescue, EYP1901 still reduced treatment burden by 34%**

# EYP-1901 Phase 1 DAVIO Study

## Case 3: Entered the Study With Subretinal Fluid

*High dose cohort (EYP-1901 3090 µg)*

### Prior to treatment

Screening Visit (8 prior anti-VEGF injections)



# EYP-1901 Phase 1 DAVIO Study

## Case 3: Post-treatment – New Fluid Doesn't Mean Rescue !

*High dose cohort (EYP-1901 3090 µg)*


















# EYP-1901 Phase 1 DAVIO Study
## 6-Month Summary - All Objectives Successfully Met

Proof of Concept for bioerodible Durasert and vorolanib in wet AMD

**SAFETY**

**Positive Safety Data**

- No ocular SAEs reported
- No drug-related systemic SAEs reported
- Ocular AEs - majority mild and to be expected

**EFFICACY**

**Positive Efficacy Data:**

- Stable VA and OCT
- Median time to rescue: 6 months
- **76 %** rescue-free up to 4 months
- **53 %** rescue-free up to 6 months
- Clinically significant reduction in treatment burden by **79 %**

# EYP-1901 Phase 1 DAVIO Study
## 8 month Update For All 17 Patients

**SAFETY**

**Continued Positive Safety Data**

- No ocular SAEs reported
- No drug-related systemic SAEs reported
- Ocular AEs - majority mild and to be expected

**DURABILITY**

**7 of 17 (41%) eyes rescue-free through 8-months follow up**

# EYP-1901 Phase 1 DAVIO Study – January 2022 Update

## Clinically Significant Reduction in Treatment Burden - *76 % for the entire cohort*

### SOC Anti-VEGF Injections Before and After Treatment




Average Monthly TX Burden

| | Prior period | Period after | ↓% |
|---|---|---|---|
| Low dose (n=3) | 0.74 | 0.22 | -66 % |
| Low-mid dose (n=1) | 0.78 | 0 | -100% |
| Mid dose (n=8) | 0.78 | 0.08 | -90% |
| High dose (n=5) | 0.59 | 0.23 | -50% |

● Anti-VEGF ○ No rescue injection given □ Missed visit

*Interim data – monitored through 6 months*

PIPELINE

# EYP-1901



VOROLANIB | DURASERT

## Phase 2 Plan

- Positive and collaborative Type C meeting held with FDA in December 2021
  - Obtained guidance on Phase 2 and pivotal studies
- Phase 2 trial in Wet AMD expected to initiate in Q3 of 2022
  - Two doses, randomized and controlled (aflibercept)
  - Approximately 144 patients across the three arms
  - Anticipate leveraging Phase 1 clinical findings and observations around biomarkers to refine Phase 2 clinical trial design
- Phase 2 trial in Diabetic Retinopathy expected to initiate in 2H 2022

# EYP-1901 Phase 1 DAVIO Study

## Retrospective Sub-Group (N=11) Analysis Based on Entry Criteria and Anticipated Dosing in Phase 2 Wet AMD Study – 86 % reduction in Treatment Burden

Subgroup Analysis of DAVIO Medium and High Dose Patients – Eliminating the 1-month Rescues

### SOC Anti-VEGF Injections Before and After Treatment




● Anti-VEGF ○ No rescue injection given □ Missed visit

**Reduction in Treatment Burden of 86 % overall**

| Mid dose (n=8) | | |
|---|---|---|
| 0.78 | 0.08 | -90% |

| High dose (n=3) | | |
|---|---|---|
| 0.62 | 0.12 | -81% |

*Interim data – monitored through 6 months*

PIPELINE

**EYP-1901**



VOROLANIB | DURASERT

# 2022 and Beyond
## Positioned to Transform the Ophthalmology Landscape

- Paradigm-shifting potential of DURASERT technology now demonstrated with multiple approved drugs and small molecule agents
  - Ability to utilize technology for small molecule agents with different MOAs
  - Ability to tailor and control dosing frequency for specific indications and patient populations
  - Ability to inject multiple implants with a single injection
- Apply new technological enhancements to DURASERT platform to further expand the scope and scale of new indications



Products

# FDA approved commercial products

PRODUCTS

0.18 mg
YUTIQ™
(fluocinolone acetonide intravitreal implant) 0.18 mg

CONTINUOUS CALM IN UVEITIS

# Approved for the treatment of chronic non-infectious uveitis affecting the back of the eye



- Commercially launched in U.S. in 2019
- Patent protection to August 2027
- Constant and stable release of fluocinolone with Durasert helps prevent uveitis flares for up to 3 years

**LICENSE AGREEMENTS**

Alimera Sciences, Inc. has rights for non-infectious posterior uveitis in the EMEA

Rights for China, Hong Kong, Taiwan, Macau , Korea and certain SE Asia countries licensed to Ocumension Therapeutics with a royalty on sales payable to EyePoint

PRODUCTS

0.18 mg
YUTIQ™
(fluocinolone acetonide intravitreal implant) 0.18 mg

CONTINUOUS CALM IN UVEITIS

# Chronic non-infectious uveitis causes blindness with every flare

**60K–100K patients are suffering from uveitis in the U.S.**

## The need

- Flares can cause blindness
- 30,000 Americans become blind each year because of uveitis
- Uveitis lasts a lifetime and often affects people in middle age
- Conventional treatment is burdensome for patients and caregivers

## The YUTIQ answer

- 3-year continuous treatment in a single injection that controls flares and preserves eyesight
- Simple administration in the physician's office
- Gives patients and physicians the confidence that comes with three years of assured compliance

PRODUCTS

0.18 mg
YUTIQ™
(fluocinolone acetonide intravitreal implant) 0.18 mg

CONTINUOUS CALM IN UVEITIS

# Continuous 3-year delivery limits blindness-causing uveitis flares

## Time to recurrence of uveitis within 36 months



PRODUCTS

0.18 mg YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg

CONTINUOUS CALM IN UVEITIS

# Record customer demand* in Q4 2021

*Customer demand is defined as units purchased by Surgery Centers or physicians from the specialty distributors.



PRODUCTS

DEXYCU
(dexamethasone intraocular suspension) 9%

TARGET THE SITE

# Treatment of inflammation following ocular surgery



- Effective January 1, 2022 sales and marketing activities to be managed by our commercial alliance partner ImprimisRX
- EyePoint to retain NDA and continue to record revenue and COGS for DEXYCU sales

- DEXYCU eligible for Category III CPT code, 0X78T for the administration of a drug into the posterior chamber of the anterior segment of the eye, effective January 1, 2022
- Centers for Medicare & Medicaid Services (CMS) extended DEXYCU pass through payment status until December 31, 2022, as part of its Hospital Outpatient Prospective Payment System Final Rule

LICENSE AGREEMENT

Rights for China, Hong Kong, Taiwan, Macau , Korea and certain SE Asia countries licensed to Ocumension Therapeutics with a royalty on sales payable to EyePoint

PRODUCTS

DEXYCU®
(dexamethasone intraocular suspension) 9%

TARGET THE SITE

# Record customer demand* in Q4 2021

*Customer demand is defined as units purchased by Surgery Centers or physicians from the specialty distributors.



DELIVERING INNOVATION TO THE EYE

# Financial Summary

## Solid cash position and growing revenues supporting strong cash runway

- ~$210 million of Cash on December 31, 2021
- $38.9 million of debt on December 31, 2021
- $8.6 million of net product revenues in Q3 2021, a 49% increase over Q3 2020
- $24.1 million of net product revenues YTD September 30, 2021, a 70% increase over YTD September 30, 2020


Delivering Innovation to the Eye
EyePoint
PHARMACEUTICALS